 - Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T- lymphocyte-associated antigen 4 CTLA-4, anti-programmed cell death1 PD-1, anti-programmed cell death ligand 1 PD-L1, or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines 